ATX 61.3% 10.0¢ amplia therapeutics limited

Ann: Phase 2 Trial in First-Line Pancreatic Cancer Patients, page-4

  1. 2,132 Posts.
    lightbulb Created with Sketch. 668
    There’s lots to like here

    “If we are able to see positive signs that AMP945 improves the leading current treatment option we will commence discussions with regulators and potential partners concerning future trials required to support product approval.”

    Positive signs ...

    This trial will be conducted in newly diagnosed patients receiving first-line therapy for pancreatic cancer.


    Looking forward to getting these trials underway ...

    .
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
(20min delay)
Last
10.0¢
Change
0.038(61.3%)
Mkt cap ! $27.42M
Open High Low Value Volume
7.0¢ 10.0¢ 7.0¢ $328.8K 3.969M

Buyers (Bids)

No. Vol. Price($)
1 13700 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 24649 1
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
ATX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.